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Introduction
Testicular germ cell tumors (TGCTs) are rare, but they 
constitute the most common malignancy in young men 
in many countries. It has been estimated that 8,480 men 
will have been diagnosed with testicular cancer in 2010 in 
the United States [1]. Established risk factors include white 
Caucasian  ethnicity,  previous  TGCT,  positive  family 
history,  infertility  or  subfertility,  cryptorchidism  (un­
descended testes), and testicular microlithiasis (cal  cium 
formations on the testicles) (reviewed in [2]). The relative 
risks  associated  with  these  clinical  factors  are  com­
paratively  high.  For  example,  a  previous  meta­analysis 
estimated that the relative risk of TGCT among men with 
cryptorchidism was 4.8 (95% confidence interval 4.0 to 
5.7) [3]. A recent evidence review for the US Preventive 
Services  Task  Force  found  no  new  evidence  in  the 
published literature on the benefits or harms of screening 
for  TGCT  that  would  affect  the  task  force’s  previous 
recommendation against screening [4].
Although genetic and environmental factors contribute 
to TGCT development, the genetic component seems to 
be particularly important. Sons of men with TGCT have 
a four­ to six­fold increased risk of TGCT cancer com­
pared  with  the  general  population,  and  brothers  of 
affected men have an eight­ to ten­fold increased risk [2]. 
Dizygotic  or  monozygotic  twin  brothers  of  men  with 
TGCT are reported to have 37­fold or 76.5­fold elevated 
risks of TGCT, respectively [2]. However, a genome­wide 
genetic linkage study of 179 families by the International 
Testicular Cancer Linkage Consortium did not provide 
strong evidence for the location of a gene predisposing to 
TGCT [2], suggesting that TGCT is a genetically complex 
and polygenic disease.
In agreement with this hypothesis, multiple risk loci that 
contribute  to  TGCT  risk  have  been  discovered.  A 
candidate study has identified a deletion in the Y chromo­
some azoospermia factor C (AZFc) region (known as the 
gr/gr deletion) as a TGCT risk locus (odds ratio (OR) = 3.2 
and 2.1 in familial and sporadic TGCT, respectively) [5]. 
Moreover, three recent TGCT genome­wide associa  tion 
studies (GWASs) from the UK [6,7] and the US [8] have 
described  several  new  risk  loci.  Single  nucleotide 
polymorphisms (SNPs) with significant associations were 
located in regions containing the genes KITLG (encoding a 
ligand for the tyrosine kinase KIT) and SPRY4 (encod  ing 
an  inhibitor  of  the  mitogen­activated  protein  kinase 
pathway  acting  downstream  of  KITLG­KIT).  Another 
asso  ciation was identified in the pro­apoptotic gene BAK1 
[6]. The most recent study identified additional risk alleles 
in  or  near  DMRT1  (which  is  involved  in  sex  deter  mi­
nation), TERT, and ATF7IP (both of which govern telo­
mere maintenance) [7]. The calculated per­allele OR for 
variants in the region of KITLG (OR = 2.69) is the highest 
reported for any malignancy to date. The ORs for the risk 
SNPs in or near the remaining genes are 1.50 (BAK1), 1.37 
(SPRY4),  1.27  (ATF7IP),  1.37  (DMRT1),  1.54  (TERT/
CLPTM1L;  CLPTM1  encodes  the  cisplatin­resistance­
related protein CRR9p and lies next to TERT), and 1.33 
(TERT). All risk SNPs combined account for an estimated 
11% of the risk to the brothers and 16% of the risk to the 
sons of individuals with TGCT, respectively [7], suggesting 
that additional risk alleles remain to be identified.
On  the  basis  of  current  US  cancer  incidence  rates, 
0.49% of white men born today will be diagnosed with 
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© 2011 BioMed Central Ltdcancer of the testis at some time during their lifetime. For 
US black men, the lifetime risk is considerably lower [1]. 
Under  a  multiplicative  model,  men  in  the  top  10%  of 
genetic risk (those with the greatest genetic risk) have a 
relative risk that is only about threefold greater than the 
general population [7]. Thus, the magnitude of risk asso­
ciated with these susceptibility alleles does not seem to 
justify  performing  testicular  cancer  risk  assessment  in 
the general population. It is currently unknown whether 
the recently identified TGCT risk loci are also etio  logi­
cally associated with standard clinical TGCT risk factors, 
such as cryptorchidism. If they were, such associations 
would imply that the genetic risk is mediated through the 
standard risk factor(s). However, if clinical factors are not 
correlated with TGCT risk variants and do not interact 
with TGCT loci as contributors to TGCT risk, a stratified 
genetic risk assessment in men with various combinations 
of  these  clinical  and  genetic  risk  factors  may  be  an 
approach that could be tested through future research. 
Indeed, our own analysis suggested that white men aged 
30 to 34 years with a history of cryptorchidism who were 
also  in  the  top  1%  of  genetic  risk  had  a  considerably 
higher  estimated  5­year  testicular  cancer  risk  than  the 
5­year testicular cancer risk of 0.087% observed in 30 to 
34  year  old  white  males  in  the  US  (CPK,  GB  and  JS, 
unpublished data).
At  present,  there  is  no  standard,  validated  screening 
strategy available for TGCT. Since TGCT treatment is 
associated with very high cure rates, including men with 
metastatic  disease,  even  a  perfect  screening  strategy 
would  have  a  minimal  impact  on  patient  survival,  the 
usual standard by which screening programs are judged. 
Consequently, early detection of these tumors ­ resulting 
in less intense treatment with fewer acute and long­term 
side effects, such as second malignant neoplasms, cardio­
vascular disease, neurotoxicity, nephrotoxicity, pulmo  nary 
toxicity, hypogonadism, decreased fertility, and psycho­
logical problems (reviewed in [9]) ­ would probably be 
the  main  goal  of  any  TGCT  screening  strategy.  Such 
screening should be tailored to the individual and should 
take into account the magnitude of the predicted risk, the 
precision  of  this  estimate,  and,  most  importantly,  the 
patient’s preferences and age. Currently available screen­
ing tools include testicular self­examination, serial trans­
scrotal  testicular  ultrasounds,  and/or  testicular  biopsy. 
Although testicular biopsy can detect carcinoma in situ, 
it  may  be  complicated  by  edema  and  hematoma.  The 
other screening modalities are not invasive but cannot 
detect carcinoma in situ. It is beyond the scope of this 
com  mentary to discuss the pros and cons of each of these 
modalities, or their psychological and economic impli­
cations. Any clinical action that might result from the use 
of a newly developed TGCT risk prediction tool would, 
of course, require validation through a clinical trial.
Conclusions
Currently, genetic risk prediction based on marker alleles 
identified through GWASs is of limited value for most 
complex  traits  [10].  TGCT  has  a  larger  genetic 
component  than  many  other  complex  diseases,  and 
recently identified risk marker alleles confer, at least in 
part, higher relative risks than those identified for other 
cancers. In addition, clinical risk factors such as positive 
family history or cryptorchidism confer higher relative 
risks  than  analogous  clinical  risk  factors  for  other 
cancers.  General  population  genetic  assessment  using 
genetic variants that modify TGCT risk currently has no 
proven value for risk prediction. Given testicular cancer’s 
rarity and the effectiveness of currently available treat­
ment regimens, it is difficult to envision a time when such 
an approach would be feasible. However, future research 
should  address  the  question  of  whether  a  stratified 
genetic risk assessment strategy may be useful for a small 
group of men, in conjunction with known clinical risk 
factors for TGCT.
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